GlassScriptPhysician profile
Margaret E Umah
NPI 1548498009
$15,223.03
in general payments reported to CMS, 2019-2025
55 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,269 · 2021: $3,399 · 2022: $2,420 · 2023: $2,843 · 2024: $2,199 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,835 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,835.45 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,627.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,327.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $1,195.88 | 2019-2025 | |
| Lilly USA, LLC | $986.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $890.62 | 2020-2025 | Ubrelvy, Linzess, Viberzi |
| Pfizer INC. | $854.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $784.70 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $713.38 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $570.16 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $482.40 | 2019-2025 | Gardasil 9, Gardasil, Steglatro |
| Abbott Laboratories | $474.98 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $474.19 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.96 | 2019-2024 | Jardiance |
| Eisai INC. | $287.56 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.54 | 2019-2023 | Trulance, Xifaxan |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $260.02 | 2024-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $256.70 | 2020-2025 | Tirosint, Licart, Flector |
| Astellas Pharma US INC | $206.17 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $180.96 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $160.92 | 2022 | |
| Dynavax Technologies Corporation | $151.45 | 2020-2023 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $141.42 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $116.23 | 2022-2023 | |
| Exact Sciences Corporation | $109.51 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $106.33 | 2021-2024 | Nexletol |
| Shield Therapeutics INC | $104.70 | 2024-2025 | |
| Optinose US, INC. | $97.22 | 2019-2024 | |
| Genentech USA, INC. | $96.36 | 2019-2021 | |
| Inspire Medical Systems, INC. | $96.33 | 2024-2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $73.96 | 2020-2023 | Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $54.70 | 2023-2025 | Gemtesa |
| Renalytix Ai, INC. | $49.59 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Currax Pharmaceuticals LLC | $46.12 | 2022-2025 | Contrave |
| Biogen, INC. | $42.41 | 2024 | Skyclarys |
| Hologic Sales and Service, LLC | $41.31 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $40.92 | 2023-2024 | Rexulti |
| Vivus LLC | $40.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $39.47 | 2025 | Symbravo |
| Melinta Therapeutics, LLC | $37.71 | 2019 | |
| Sanofi Pasteur INC. | $35.58 | 2020-2023 | |
| Scilex Pharmaceuticals INC. | $32.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.28 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $28.71 | 2019 | |
| Allergan, INC. | $28.14 | 2020 | |
| Arbor Pharmaceuticals, INC. | $26.84 | 2021-2022 | |
| Redhill Biopharma INC. | $25.68 | 2021 | |
| Organon LLC | $25.44 | 2023 | Nexplanon |
| Mylan Specialty L.P. | $23.08 | 2023 | Yupelri |
| Ascendis Pharma Endocrinology INC | $21.06 | 2025 | Yorvipath |
| Alvogen INC | $20.05 | 2024 | Teriparatide |
| Idorsia Pharmaceuticals US INC | $18.92 | 2023 | Quviviq |
| Mission Pharmacal Company | $16.03 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.83 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.60 | 2023 | Edarbi |
| Senseonics, Incorporated | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Umah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.